https://www.selleckchem.com/pr....oducts/salinosporami
The safety and efficacy of subcutaneous immune globulin 20% (human) solution (Cuvitru; Ig20Gly) for primary immunodeficiency disease (PID) have been demonstrated in 2 pivotal trials. To describe patient characteristics and infusion parameters of patients with PID initiating Ig20Gly outside of a clinical trial setting. This retrospective, observational study analyzed records of patients participating in the HelloCuvitru program, a patient support program in the United States providing Ig20Gly free of charge f
Like
Comment
Share
